Log In
BCIQ
Print this Print this
 

Biosimilar golimumab (BOW100)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of golimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$14.1M

$5.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/09/2015

$14.1M

$5.1M

0

Get a free BioCentury trial today